Physician profile
Charles E Smith
NPI 1376589085
$697.32
in general payments reported to CMS, 2019-2025
11 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.71 · 2023: $164 · 2024: $211 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $218.49 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $154.00 | 2023-2024 | |
| Pfizer INC. | $78.71 | 2024-2025 | |
| Novo Nordisk INC | $62.73 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $39.69 | 2023 | Invega Sustenna |
| Actelion Pharmaceuticals US, INC. | $35.63 | 2025 | Uptravi, Opsumit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.20 | 2025 | Caplyta |
| Lilly USA, LLC | $28.76 | 2022-2025 | Mounjaro |
| Boston Scientific Corporation | $17.83 | 2022 | |
| Abbvie INC. | $15.52 | 2025 | |
| Exact Sciences Corporation | $13.76 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.